Replies to post #243416 on Biotech Values

[vinmantoo]

Before moving to the financials, I want to address briefly our ongoing patent litigation in which we are seeking damages for Pfizer's infringement of our issued 953 patent in the manufacture, use and sale of its COVID-19 antiviral paxlobid.

We recognize the importance of paxlovid's availability for patients and we do not intend to seek an injunction or take other action in this litigation to impede the production, sale or distribution of paxlovid. And finally, in this lawsuit, we are taking steps to ensure that we will be fairly compensated for our intellectual property. Importantly, our 953 patent is completely separate from the patent estate covering our discovery of EDP-235 and our ongoing antiviral discovery work for coronaviruses. Indeed, we have a growing 3CL protease inhibitor patent estate, including several issued U.S. patents, one of which covers EDP-235. These patents describe compounds built on an independent and distinct chemical scaffold from the one described in the 953 patent and in Pfizer's patents for paxlovid.

Thanks Dew for the link. That sounds positive. The above is something else that I thought was interesting and quite positive. No matter how the lawsuit against PFE over Paxlovid goes, EDP-235 won't be affected.

All in all, I am feeling more confident than ever about ENTA as they seem to be moving forward on multiple fronts, otherwise known as firing on all cylinders.

[DewDiligence]

ENTA opens $100M ATM with Jefferies:

https://www.sec.gov/Archives/edgar/data/0001177648/000119312522231299/d396056d424b5.htm

ENTA had ~$330M of pro forma cash at 6/30/22 (#msg-169621212), so the ATM looks like a backup contingency in case ENTA decides to conduct the phase-2(/3) EDP-235 trial without a partner.

p.s. ENTA has never raised capital as a public company apart from its 2013 IPO. HCV milestones and royalties from ABBV have been sufficient to fund ENTA's operations.